<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38142603</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>331</Volume><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>The association between suspected long-COVID and stimulant prescribing in the United States.</ArticleTitle><Pagination><StartPage>115686</StartPage><MedlinePgn>115686</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2023.115686</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(23)00636-4</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study sought to determine the association between suspected long-COVID and receipt of a stimulant prescription among persons diagnosed with COVID-19 and to describe clinical and demographic factors associated with receiving a stimulant prescription.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">US patients 18 and older who had a COVID-19 diagnosis or a positive COVID-19 PCR test from April 1st, 2020 through December 21st, 2022 recorded in a national electronic health record data set obtained from TriNetX were assessed. Comparison subjects were propensity score matched on baseline covariates to those with a symptom of or diagnosis of long-COVID. A Cox Proportional Hazards models was used to estimate the influence of long-COVID on stimulant prescription receipt.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Those with long-COVID (n&#xa0;=&#xa0;65,329) were twice as likely to be prescribed a stimulant as persons with only acute COVID-19 (n&#xa0;=&#xa0;189,438, HR=2.162; 1.929-2.423). Among persons with long-COVID, persons with new onset ADHD (HR=7.196; 5.749- 9.007), opioid-related disorders (HR=2.140; 1.264-3.621) and mood disorders (HR=1.649; 1.336-2.035) were more likely to be prescribed a stimulant.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Further research describing the risks associated with increased stimulant use among persons with long-COVID is warranted.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koonce</LastName><ForeName>Ruston M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Division of Pharmaceutical Evaluation and Policy, College of Pharmacy, University of Arkansas for Medical Sciences, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Bradley C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Division of Pharmaceutical Evaluation and Policy, College of Pharmacy, University of Arkansas for Medical Sciences, United States of America. Electronic address: bmartin@uams.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 DA022981</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003107</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="Y">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long&#x2013;COVID</Keyword><Keyword MajorTopicYN="N">Stimulant</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>2</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>25</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>24</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38142603</ArticleId><ArticleId IdType="mid">NIHMS1955451</ArticleId><ArticleId IdType="pmc">PMC10797645</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2023.115686</ArticleId><ArticleId IdType="pii">S0165-1781(23)00636-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cohen K, Ren S, Heath K, et al. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. Published online February 9, 2022:e068414. doi:10.1136/bmj-2021-068414</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068414</ArticleId><ArticleId IdType="pmc">PMC8828141</ArticleId><ArticleId IdType="pubmed">35140117</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23(2):194&#x2013;202. doi:10.1038/s41590-021-01104-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID or Post-COVID Conditions &#x2223; CDC. Accessed January 31, 2023. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html</Citation></Reference><Reference><Citation>Rubin R. As Their Numbers Grow, COVID-19 &#x201c;Long Haulers&#x201d; Stump Experts. JAMA. 2020;324(14):1381. doi:10.1001/jama.2020.17709</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17709</ArticleId><ArticleId IdType="pubmed">32965460</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021;53(10):737&#x2013;754. doi:10.1080/23744235.2021.1924397</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784. doi:10.1371/journal.pone.0240784</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240784</ArticleId><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EJ, Williams DM, Walker AJ, et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13(1):3528. doi:10.1038/s41467-022-30836-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30836-0</ArticleId><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. The Lancet. 2021;398(10302):747&#x2013;758. doi:10.1016/S0140-6736(21)01755-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022;226(9):1593&#x2013;1607. doi:10.1093/infdis/jiac136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. The Lancet. 2022;399(10343):2263&#x2013;2264. doi:10.1016/S0140-6736(22)00941-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KGI, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27(9):1607&#x2013;1613. doi:10.1038/s41591-021-01433-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly JD, Curteis T, Rawal A, et al. SARS-CoV-2 post-acute sequelae in previously hospitalised patients: systematic literature review and meta-analysis. European Respiratory Review. 2023;32(169):220254. doi:10.1183/16000617.0254-2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0254-2022</ArticleId><ArticleId IdType="pmc">PMC10336551</ArticleId><ArticleId IdType="pubmed">37437914</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmati M, Udeh R, Yon DK, et al. A systematic review and meta-analysis of long-term sequelae of COVID-19 2-year after SARS-CoV-2 infection: A call to action for neurological, physical, and psychological sciences. J Med Virol. 2023;95(6). doi:10.1002/jmv.28852</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28852</ArticleId><ArticleId IdType="pubmed">37288652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2022;101:93&#x2013;135. doi:10.1016/j.bbi.2021.12.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanbehzadeh S, Zanjari N, Yassin M, Yassin Z, Tavahomi M. Association between long COVID, functional activity, and health-related quality of life in older adults. BMC Geriatr. 2023;23(1):40. doi:10.1186/s12877-023-03757-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-023-03757-w</ArticleId><ArticleId IdType="pmc">PMC9868494</ArticleId><ArticleId IdType="pubmed">36690948</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), Royal College of General Practitioners (RCGP). COVID-19 Rapid Guideline: Managing the Longterm Effects of COVID-19.; 2022.</Citation></Reference><Reference><Citation>CDC. Post-COVID Conditions: Information for Healthcare Providers. Accessed January 31, 2023. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html</Citation></Reference><Reference><Citation>From skepticism to insurance denials, long COVID patients face more than only health challenges &#x2013; New Hampshire Bulletin. Accessed February 1, 2023. https://newhampshirebulletin.com/2022/06/01/from-skepticism-to-insurance-denials-long-covid-patients-face-more-than-only-health-challenges/</Citation></Reference><Reference><Citation>Exploring Long COVID: Symptoms, Diagnosis and Management - Penn Medicine. Accessed February 1, 2023. https://www.pennmedicine.org/research-at-penn/online-research-interviews/exploring-long-covid-symptoms-diagnosis-and-management</Citation></Reference><Reference><Citation>New Long-Haul COVID Clinics Treat Mysterious and Ongoing Symptoms - Scientific American. Accessed February 1, 2023. https://www.scientificamerican.com/article/new-long-haul-covid-clinics-treat-mysterious-and-ongoing-symptoms/</Citation></Reference><Reference><Citation>Pary R, Scarff JR, Jijakli A, Tobias C, Lippmann S. A Review of Psychostimulants for Adults With Depression. Fed Pract. 2015;32(Suppl 3):30S&#x2013;37S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375494</ArticleId><ArticleId IdType="pubmed">30766117</ArticleId></ArticleIdList></Reference><Reference><Citation>Patkar AA, Masand PS, Pae CU, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26(6):653&#x2013;656. doi:10.1097/01.JCP.0000246212.03530.FD</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.JCP.0000246212.03530.FD</ArticleId><ArticleId IdType="pubmed">17110825</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindran AV, Kennedy SH, O&#x2019;Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2008;69(1):87&#x2013;94. doi:10.4088/JCP.V69N0112</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.V69N0112</ArticleId><ArticleId IdType="pubmed">18312042</ArticleId></ArticleIdList></Reference><Reference><Citation>van Bronswijk S, Moopen N, Beijers L, Ruhe HG, Peeters F. Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression. Psychol Med. 2019;49(3):366&#x2013;379. doi:10.1017/S003329171800199X</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S003329171800199X</ArticleId><ArticleId IdType="pubmed">30139408</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennissen L, Bakker MJ, Banaschewski T, et al. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS Drugs. 2017;31(3):199&#x2013;215. doi:10.1007/s40263-017-0410-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-017-0410-7</ArticleId><ArticleId IdType="pmc">PMC5336546</ArticleId><ArticleId IdType="pubmed">28236285</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344&#x2013;350. doi:10.1097/YCO.0000000000000717</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0000000000000717</ArticleId><ArticleId IdType="pmc">PMC8154745</ArticleId><ArticleId IdType="pubmed">33965972</ArticleId></ArticleIdList></Reference><Reference><Citation>TriNetX &#x2223; Our real-world data by therapeutic area and world region. Accessed February 12, 2023. https://trinetx.com/real-world-data/</Citation></Reference><Reference><Citation>Kolar D, Keller A, Golfinopoulos M, Cumyn L, Syer C, Hechtman L. Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat. 2008;4(2):389&#x2013;403. doi:10.2147/ndt.s6985</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ndt.s6985</ArticleId><ArticleId IdType="pmc">PMC2518387</ArticleId><ArticleId IdType="pubmed">18728745</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff ER, Madlock-Brown C, Baratta JM, et al. Coding Long COVID: Characterizing a new disease through an ICD-10 lens. medRxiv. Published online September 2, 2022. doi:10.1101/2022.04.18.22273968</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.04.18.22273968</ArticleId><ArticleId IdType="pmc">PMC9931566</ArticleId><ArticleId IdType="pubmed">36793086</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380:e072529. doi:10.1136/BMJ-2022-072529</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJ-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (HCUP). CLINICAL CLASSIFICATIONS SOFTWARE REFINED (CCSR) FOR ICD-10-CM DIAGNOSES, V2022.1.; 2021.</Citation></Reference><Reference><Citation>Nearly One in Five American Adults Who Have Had COVID-19 Still Have &#x201c;Long COVID.&#x201d;
Centers for Disease Control and Prevention. Published June
22, 2022. Accessed September 26, 2023. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm</Citation></Reference><Reference><Citation>Ferrara F, Zavaleta E, Vitiello A, et al. The direct correlation between Covid-19 and Attention Deficit/Hyperactivity Disorder (ADHD). Eur Neuropsychopharmacol. 2023;73:62&#x2013;64. doi:10.1016/j.euroneuro.2023.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2023.04.010</ArticleId><ArticleId IdType="pmc">PMC10121130</ArticleId><ArticleId IdType="pubmed">37121166</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunill R, Castells X, Tobias A, Capell&#xe0; D. Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients. Psychopharmacology (Berl). 2016;233(2):187&#x2013;197. doi:10.1007/s00213-015-4099-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-015-4099-3</ArticleId><ArticleId IdType="pubmed">26446868</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Z, Lichtenstein P, Halldner L, et al. Stimulant ADHD medication and risk for substance abuse. Journal of Child Psychology and Psychiatry. 2014;55(8):878&#x2013;885. doi:10.1111/jcpp.12164</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpp.12164</ArticleId><ArticleId IdType="pmc">PMC4147667</ArticleId><ArticleId IdType="pubmed">25158998</ArticleId></ArticleIdList></Reference><Reference><Citation>Nittas V, Gao M, West EA, et al. Long COVID Through a Public Health Lens: An Umbrella Review. Public Health Rev. 2022;43. doi:10.3389/phrs.2022.1604501</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/phrs.2022.1604501</ArticleId><ArticleId IdType="pmc">PMC8963488</ArticleId><ArticleId IdType="pubmed">35359614</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbate G, De Iulio B, Thomas G, et al. Postural Orthostatic Tachycardia Syndrome After COVID-19: A Systematic Review of Therapeutic Interventions. J Cardiovasc Pharmacol. 2023;82(1):23&#x2013;31. doi:10.1097/FJC.0000000000001432</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0000000000001432</ArticleId><ArticleId IdType="pubmed">37094584</ArticleId></ArticleIdList></Reference><Reference><Citation>Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. BMC Cardiovasc Disord. 2012;12:41. doi:10.1186/1471-2261-12-41</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2261-12-41</ArticleId><ArticleId IdType="pmc">PMC3405448</ArticleId><ArticleId IdType="pubmed">22682429</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo P, Benito Ballesteros A, Yeung SP, et al. COVCOG 2: Cognitive and Memory Deficits in Long COVID: A Second Publication From the COVID and Cognition Study. Front Aging Neurosci. 2022;14. doi:10.3389/fnagi.2022.804937</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.804937</ArticleId><ArticleId IdType="pmc">PMC8967943</ArticleId><ArticleId IdType="pubmed">35370620</ArticleId></ArticleIdList></Reference><Reference><Citation>Sassi KLM, Rocha NP, Colpo GD, John V, Teixeira AL. Amphetamine Use in the Elderly: A Systematic Review of the Literature. Curr Neuropharmacol. 2020;18(2):126&#x2013;135. doi:10.2174/1570159X17666191010093021</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X17666191010093021</ArticleId><ArticleId IdType="pmc">PMC7324882</ArticleId><ArticleId IdType="pubmed">31660835</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougall D, Poole N, Agrawal N. Pharmacotherapy for chronic cognitive impairment in traumatic brain injury. Cochrane Database Syst Rev. 2015;(12):CD009221. doi:10.1002/14651858.CD009221.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009221.pub2</ArticleId><ArticleId IdType="pmc">PMC11092927</ArticleId><ArticleId IdType="pubmed">26624881</ArticleId></ArticleIdList></Reference><Reference><Citation>Palis H, Xavier C, Dobrer S, et al. Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study. BMC Public Health. 2022;22(1):2084. doi:10.1186/s12889-022-14506-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-14506-w</ArticleId><ArticleId IdType="pmc">PMC9664696</ArticleId><ArticleId IdType="pubmed">36380298</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute on Drug Abuse. Drug Overdose Death Rates. Published June
30, 2023. Accessed September 6, 2023. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates</Citation></Reference><Reference><Citation>Taquet M, Sillett R, Zhu L, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. 2022;9(10):815&#x2013;827. doi:10.1016/S2215-0366(22)00260-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(22)00260-7</ArticleId><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Substance Abuse and Mental Health Services Administration. IDENTIFICATION AND MANAGEMENT OF MENTAL HEALTH SYMPTOMS AND CONDITIONS ASSOCIATED WITH LONG COVID.; 2023. www.samhsa.gov</Citation></Reference><Reference><Citation>Center for Behavioral Health Statistics S. Key Substance Use and Mental Health Indicators in the United States: Results from the 2021 National Survey on Drug Use and Health.; 2022.</Citation></Reference><Reference><Citation>US Food and Drug Administration. FDA requires updates to clarify labeling of prescription stimulants used to treat ADHD and other conditions.</Citation></Reference><Reference><Citation>Fung KW, Baye F, Baik SH, Zheng Z, McDonald CJ. Prevalence and characteristics of long COVID in elderly patients: An observational cohort study of over 2 million adults in the US. PLoS Med. 2023;20(4):e1004194. doi:10.1371/journal.pmed.1004194</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1004194</ArticleId><ArticleId IdType="pmc">PMC10150975</ArticleId><ArticleId IdType="pubmed">37068113</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>